
Zydus Cadila scores twin FDA approvals
pharmafile | February 17, 2017 | News story | Medical Communications, Sales and Marketing | FDA, Zydus Cadila
Indian pharmaceutical firm Zydus Cadila has announced that the US Food and Drug Administration (FDA) has given the go-ahead for the marketing and sale of two of its products in the US, bringing the firm’s total drug approvals to more than 100 since 2004.
“Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg and 200 mg and Clobetasol Propionate spray, 0.05%,” the company revealed in a BSE filing.
Fluconazole is an antifungal medication, a generic version of Bayer’s Canesten. It is used to treat a range of fungal infections by inhibiting the fungal cytochrome P450 enzyme 14α-demethylase. Clobetasol Propionate is used as a treatment for various skin disorders.
Zydus made news in September last year when it was swept up in a lawsuit from Pfizer, alongside a number of Indian drug companies including Sun Pharma, for allegedly attempting to copy its rheumatoid arthritis treatment Xeljanz.
Matt Fellows
Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …

FDA approves Moderna’s updated COVID-19 vaccines targeting new variant
The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …






